ABALOPARATIDE
| Brand name | TYMLOS |
|---|---|
| Active ingredient | ABALOPARATIDE |
| Strength | 3.12MG/1.56ML (2MG/ML) |
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Modality | Small molecule |
| FDA approval | April 2017 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11680942 | January 2040 | use U-3322 |
| 11255842 | January 2040 | use U-3322 |
| 10996208 | April 2038 | product |
| 11782041 | April 2038 | product |
| 11977067 | April 2038 | product |
| 7803770 | April 2031 | use U-2009 |
| RE49444 | April 2031 | use U-3543 |
| 8148333 | November 2027 | product |
| 8748382 | October 2027 | use U-2009 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.